Marie Curie Initial Training Network

Dr Anne Richter
Miltenyi Biotech GmbH

Miltenyi Biotec GmbH was founded in 1989, utilizing the development of Magnetic Cell Sorting as the strategy for market entry. The company has more than 1300 employees worldwide and sells more than 1800 products in the field of biotechnology and medical engineering, especially in the area of haematology and immunology, but we also have expertise in molecular biology and neurobiology.

Research and product development are mainly carried out in the headquarters located in Bergisch Gladbach, Germany, with more than 250 employees working in Research & Development finding solutions for research and clinical applications. It is a thriving and exciting company with a wealth of expertise in training researchers.

Based on our expertise and world-wide contacts with researchers and clinicians in the field of haematology and immunology, we are able to provide an excellent research environment to investigate new strategies to improve the clinical outcome of allogeneic haematopoietic stem cell transplantation, the main curative therapy for hematopoietic malignancies and inherited disorders.

Research Network Team

Dr. Anne Richter is senior scientist in the Research & Development Immunology department, supervising five colleagues, including one PhD student.

Recruited Fellows

Michael Lutteropp (Germany) Experienced Researcher.

Dr Lutteropp is a stem cell biologist and immunologist. He graduated from Frankfurt University in 2008 and received his PhD from the University of Oxford in 2013 after submitting a thesis titled “The emergence and early fate decisions of stem and progenitor cells in the haematopoietic system”. His technical expertise reaches from single cell techniques, particularly in vitro culture methods for the detection of lineage potentials of haematopoietic cells, over the work with in vivo models to multicolour flow cytometry and cell sorting. His current research focusses on the development of cellular immunotherapies for the treatment of haematologic cancers.

Dr Lutteropp is a co-author on several articles published in peer reviewed international scientific journals.

Project Title:Development of genetically modified Tcells to target leukemic cells.

Michael completed his project as a Marie Curie Fellow in February 2015. His results will be published in due course.

Relevant References

Visit our website at www.miltenyibiotec.com.

Anne Richter